Scribd Logo
Upload

Welcome to Scribd!

  • 27 views

    Covid 19

    Uploaded by

    aliaa
    The document discusses COVID-19, caused by the SARS-CoV-2 virus. It shares that SARS-CoV-2 is similar to the SARS coronavirus and uses the same receptor, ACE2, for cell entry. Two types of the virus, L and S, have been identified. Person-to-person spread is thought to mainly occur via respiratory droplets within 6 feet. The incubation period is up to 14 days with most cases around 4-5 days. Reported severity ranges from mild symptoms in 81% of cases to critical in 5% with an overall 4.6% fatality rate.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd

    Covid 19

    Uploaded by

    aliaa
    27 views16 pages
    The document discusses COVID-19, caused by the SARS-CoV-2 virus. It shares that SARS-CoV-2 is similar to the SARS coronavirus and uses the same receptor, ACE2, for cell entry. Two types of the virus, L and S, have been identified. Person-to-person spread is thought to mainly occur via respiratory droplets within 6 feet. The incubation period is up to 14 days with most cases around 4-5 days. Reported severity ranges from mild symptoms in 81% of cases to critical in 5% with an overall 4.6% fatality rate.

    Original Title

    COVID 19

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The document discusses COVID-19, caused by the SARS-CoV-2 virus. It shares that SARS-CoV-2 is similar to the SARS coronavirus and uses the same receptor, ACE2, for cell entry. Two types of the virus, L and S, have been identified. Person-to-person spread is thought to mainly occur via respiratory droplets within 6 feet. The incubation period is up to 14 days with most cases around 4-5 days. Reported severity ranges from mild symptoms in 81% of cases to critical in 5% with an overall 4.6% fatality rate.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    27 views16 pages

    Covid 19

    Uploaded by

    aliaa
    The document discusses COVID-19, caused by the SARS-CoV-2 virus. It shares that SARS-CoV-2 is similar to the SARS coronavirus and uses the same receptor, ACE2, for cell entry. Two types of the virus, L and S, have been identified. Person-to-person spread is thought to mainly occur via respiratory droplets within 6 feet. The incubation period is up to 14 days with most cases around 4-5 days. Reported severity ranges from mild symptoms in 81% of cases to critical in 5% with an overall 4.6% fatality rate.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 16

    COVID 19

    Ahmad dalashi
    • The virus that causes COVID-19 is designated severe acute respiratory
    syndrome coronavirus 2 (SARS-CoV-2)
    • The structure of the receptor-binding gene region is very similar to that of
    the SARS coronavirus, and the virus has been shown to use the same
    receptor, the angiotensin-converting enzyme 2 (ACE2), for cell entry.
    • In a phylogenetic analysis of 103 strains of SARS-CoV-2 from China, two
    different types of SARS-CoV-2 were identified, designated type L (accounting
    for 70 percent of the strains) and type S (accounting for 30 percent).
    • The L type predominated during the early days of the epidemic in China, but
    accounted for a lower proportion of strains outside of Wuhan than in
    Wuhan. The clinical implications of these findings are uncertain.
    Route of transmission
    •  Understanding of the transmission risk is incomplete.
    • Person-to-person spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    is thought to occur mainly via respiratory droplets, resembling the spread of influenza.
    • With droplet transmission, virus released in the respiratory secretions when a person with
    infection coughs, sneezes, or talks can infect another person if it makes direct contact with
    the mucous membranes; infection can also occur if a person touches an infected surface
    and then touches his or her eyes, nose, or mouth.
    • Droplets typically do not travel more than six feet (about two meters) and do not linger in
    the air. Although one letter to the editor described a study in which SARS-CoV-2 remained
    viable in experimentally generated aerosols for at least three hours, the relevance of this
    to the epidemiology of COVID-19 and its clinical implications are unclear
    • Given the current uncertainty regarding transmission mechanisms, airborne precautions
    are recommended in certain situations. 
    • SARS-CoV-2 RNA has been detected in blood and stool specimens.
    Live virus has been cultured from stool in some cases, but according
    to a joint WHO-China report, fecal-oral transmission did not appear to
    be a significant factor in the spread of infection
    • Viral RNA levels appear to be higher soon after symptom onset
    compared with later in the illness ; this raises the possibility that
    transmission might be more likely in the earlier stage of infection, but
    additional data are needed to confirm this hypothesis.
    • Incubation period — The incubation period for COVID-19 is thought
    to be within 14 days following exposure, with most cases occurring
    approximately four to five days after exposure.
    • In a study of 1099 patients with confirmed symptomatic COVID-19,
    the median incubation period was four days (interquartile range two
    to seven days)
    Spectrum of illness severity
    The spectrum of symptomatic infection ranges from mild to critical; most
    infections are not severe . Specifically, in a report from the Chinese Center for
    Disease Control and Prevention that included approximately 44,500 confirmed
    infections with an estimation of disease severity:
    ●Mild (no or mild pneumonia) was reported in 81 percent.
    ●Severe disease (eg, with dyspnea, hypoxia, or >50 percent lung involvement on
    imaging within 24 to 48 hours) was reported in 14 percent.
    ●Critical disease (eg, with respiratory failure, shock, or multiorgan dysfunction)
    was reported in 5 percent.
    ●The overall case fatality rate was 4.6%; no deaths were reported among
    noncritical cases.

    You might also like